Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine if Thalidomide modulates the production of HIV-suppressor factors (MIP-1 alpha,
MIP-1 beta, Rantes) and TH1 type cytokines (IL-12 and INF-gamma) in HIV-infected patients and
alters viral load.
Phase:
N/A
Details
Lead Sponsor:
Louisiana State University Health Sciences Center in New Orleans